Whitehawk Therapeutics is a clinical-stage oncology company developing three antibody-drug conjugates (ADCs) for solid tumors. An ADC attaches a cytotoxic drug payload to an antibody that targets a protein expressed on tumor cells, enabling targeted delivery while limiting damage to healthy tissue. Whitehawk was formerly known as Aadi Biosciences, and divested its only commercial product in early 2025 to relaunch as a pure-play ADC company. Whitehawk in-licensed its three pipeline candidates from WuXi Biologics and Hangzhou DAC Biotechnology: HWK-007 (targeting PTK7, in Phase 1 for NSCLC and gynecological cancers), HWK-016 (targeting membrane-bound MUC16, in Phase 1 for ovarian and endometrial cancers), and HWK-206 (targeting SEZ6 in small cell lung cancer, with an IND planned for mid-2026). All three use Hangzhou DAC's CPT113 linker-payload platform, which Whitehawk argues delivers superior linker stability, a modified exatecan payload designed to reduce bone marrow toxicity, and a novel cleavage mechanism that only releases the payload inside tumor cells. Whitehawk's core strategy is to pursue targets where first-generation ADCs demonstrated clinical efficacy but were discontinued due to toxicity from older payloads, betting that the CPT113 platform can replicate or improve efficacy with a better safety profile. Whitehawk operates as a virtual company with 23 employees, outsourcing manufacturing and clinical development, and expects its roughly $170-180M cash position to fund operations into 2028, covering anticipated Phase 1 data readouts for all three programs.